Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Revenue (2021)

Cullinan Therapeutics (CGEM) has 1 years of Revenue data on record, last reported at $18.9 million in Q1 2021.

  • For Q1 2021, Revenue changed N/A year-over-year to $18.9 million; the TTM value through Dec 2021 reached $18.9 million, changed N/A, while the annual FY2021 figure was $18.9 million, N/A changed from the prior year.
  • Revenue reached $18.9 million in Q1 2021 per CGEM's latest filing.
  • Across five years, Revenue topped out at $18.9 million in Q1 2021 and bottomed at $18.9 million in Q1 2021.